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Recently, professional and healthcare-related entities have launched frameworks designed to assess the value of
cancer innovations in multistakeholder decision processes. Among the most visible entities that propose and
implement value frameworks in oncology are the European Society of Medical Oncology (ESMO), the American
Society of Clinical Oncology (ASCO), the Memorial Sloan Kettering Cancer Center (MSKCC) and the National
Comprehensive Cancer Network (NCCN). However, these value frameworks have been criticized for conceptual
inconsistencies, inability to include a greater variety of value criteria, and inadequate explanation of the
uncertainty approach used in the modeling process. On the other hand, Multi-Criteria Decision Analysis (MCDA)
is a set of methods and processes that allow the multiple criteria involved in a decision to be explicitly addressed.
This approach allows the identification of relevant decision criteria, gathering of evidence based on scientific
literature, attribution of weights to the criteria and scores to the evidence raised, and aggregation of the
weighted scores to constitute a global metric of value. The purpose of this article is to review the main features
of these value frameworks in oncology and the importance of perspective for framework readiness to support
healthcare decision-making based on MCDA methodology.
KEYWORDS: Neoplasms; Drug Costs; Decision Support Techniques; Clinical Decision-Making; Medical Oncology;
Resource Allocation.
’ INTRODUCTION
International estimates have shown that deaths from onco-
logical disease ranked second among the different causes of
death, totaling 8.2 million deaths in 2012. A significant incre-
ase in new cases, approximately 70%, is expected over the
next two decades (1).
In Brazil, in the 2016-2017 biennium, the incidence of new
cases of cancer was estimated at approximately 600,000, of
which 420,000 were considered nonmelanoma skin cancer.
The epidemiological profile observed resembles that of
Latin America and the Caribbean, where prostate cancers
(61 thousand) in men and breast (58 thousand) in women are
the most frequent (2).
Because cancer is an emerging issue in industrialized
and nonindustrialized countries, pharmaceutical companies
are investing heavily in oncological research, and many new
and effective treatments are being developed. Together with
other economic and demographic trends, however, this
emphasis causes anticancer drugs to place an increasing
strain on global healthcare budgets (3).
In recent years, escalating drug prices have alarmed health-
care professionals and led to concerns about the government’s
role in regulating prices, and it has been suggested that, in
some instances, drug launch prices may not be proportional to
the health benefit they provide (3). Thus, many initiatives
aimed at measuring and communicating the value of new
technologies have been proposed as decision support alter-
natives in this context of increasing spending on healthcare
technologies (4).
Some breakthroughs have been recognized. First, the
development of frameworks for the evaluation of diagnostic
and therapeutic technologies has been considered promising.
Concerns about the progressive increase in drug costs are
to be expected in a scenario of demographic and epidemio-
logical transition, but justifications based exclusively on
research, development and production costs by the pharma-
ceutical industry could be considered an inadequate strategy.
On the other hand, a change in focus to prioritize what the
general population considers therapeutic value, that is, what
is truly desired from a healthcare intervention, could not
only encourage the industry to produce products with higher
added value but also stimulate innovation.
For the most part, value considerations could be made
without the aid of formal decision support systems using
intuitive approaches. However, when multiple factors may
be implicated in healthcare decisions and outcomes – for
example, in oncology, many choices are complex and involve
several therapeutic options that imply varying degrees ofDOI: 10.6061/clinics/2018/e470s
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preference for patients and healthcare providers – using such
an approach can contribute to the decision-making process.
Some of the key contributions of a decision support system
are to enable a patient-centered approach, facilitate delib-
erative processes, assist in accessing relevant evidence and
improve the effectiveness of decision-making.
The purpose of this article is to review the main chara-
cteristics of 4 of the most notable value frameworks in
oncology and the importance of perspective for framework
readiness to support health care decision-making among
the intended stakeholders, using the Multi-Criteria Decision
Analysis (MCDA) methodology as a reference.
Value and perspective
Value is a multidimensional concept encompassing differ-
ent aspects such as utility, social meaning, and emotional,
spiritual and monetary significance. A wide range of disci-
plines have proposed varying sets of elements to consider
what constitutes ‘‘value’’ (5).
Health economists define value based on what individuals
would be willing to pay to access healthcare or other related
services. Considering microeconomic principles, the idea of
‘‘willingness to pay’’ needs to consider the ‘‘opportunity
cost’’, that is, how much benefit people are willing to give up
to obtain these extra health benefits (6,7). Despite the in-
trinsic relationship between value and efficiency, this relation-
ship may not be clear with respect to healthcare interventions,
especially for new technologies. For healthcare economic
evaluation, the ‘‘net value’’ of a new intervention is an exp-
ression of the willingness to pay for health benefits in terms
of the opportunity cost of the necessary resources to obtain
the health benefit. In general terms, achieving ‘‘economic
efficiency’’ is to maximize the value obtained with the inves-
ted resource in relation to other possible allocations of the
same resource (8-10).
However, the perspectives of individuals and organizations
involved in a decision-making process can impact certain
value attributes in an evaluation process. The importance of
perspective is increasingly being considered in the recently
proposed value frameworks in oncology (11) (Table 1). What
are the appropriate criteria or attributes of value? How could
we obtain weights for the criteria considered by different
stakeholders? How should these criteria be combined to
obtain a general score? As these frameworks highlight, the
particular ‘‘perspective’’ considered is a central question.
Notably, guidelines for cost-effectiveness analysis (CEA)
emphasize the importance of clearly specifying from which
perspective the analysis is being conducted (7,12,13).
Different results can be obtained if this point of view is that
of the health plan payer, the patient, the managers, the
provider, the manufacturer of the technology, the specialties
societies, or the general society. A sound healthcare economic
evaluation could be conducted from any of these stake-
holders’ perspectives, depending on the scope and context of
the analysis.
In CEA, it has been recommended that at least 2 pers-
pectives should be considered, that of the health sector and
that of society as a whole. However, any of the above
perspectives could be considered individually (12,13).
Table 1 presents four recently developed value framework
proposals. The difference in perspectives and contexts is
striking among them, although they have been developed
from the same normative view (Figure 1).
As summarized in Table 1, in general, different stake-
holders may have more or less broad perspectives, depend-
ing on the context in which they are inserted. For example,
a patient may care about health benefits only if he or she is in
a context of ‘‘zero out of pocket’’ costs. A provider may be
concerned only with the scarce medical resources required
for the provision of a service, without worrying about the
nonmedical costs borne by the patient. An employer may
consider only costs related to absenteeism or presenteeism.
An individual hesitating to acquire a new health insurance
plan may worry about the costs and benefits of broader
coverage. In general, all these perspectives are not broad
enough to encompass all the aspects involved in the costs
and effects of a healthcare technology. Despite the bias of
each perspective, the important factor to the decision-maker
is considering what might be lacking from their own
perspective and how to make it as broad as possible if the
goal is to maximize social well-being. In this sense, the great
challenge would be how to face hard decisions considering
multiple perspectives.
In a market society, using the two hats of the subscriber
and the potential patient, the individual can make decisions
based on the vision of these two different agents, who
asymmetrically prioritize the costs and benefits of interven-
tions, aided by the varying perspectives. Meanwhile, in
universal healthcare systems, the individual can be seen as a
collective or multi-stakeholder agent using two or even more
hats. As a result, to assist such decisions, value frameworks
should reasonably support stakeholders with divergent
perspectives, considering that conflicts may exist and that
trade-offs need to be made based on what each of the parties
considers as an acceptable benefit.
Value frameworks in oncology
Recently, to support multistakeholder decision-making,
a number of healthcare-related and scientific societies have
launched frameworks designed to assess the value of
oncology therapies. These frameworks vary in terms of their
concept of value, target audience, methodology, and stage of
development (14-18).
Although healthcare organizations differ in their objec-
tives, scope of activities and methodological approaches, the
idea of implementing value assessment frameworks has been
pursued by some of them. Among the most prominent
entities, we can quote the European Society of Medical
Oncology (ESMO), the American Society of Clinical Oncol-
ogy (ASCO), the Institute of Clinical and Economic Research
(ICER), Memorial Sloan Kettering Cancer Center (MSKCC)
and the National Comprehensive Cancer Network (NCCN).
Currently, these entities have proposed some of the most
widespread value frameworks to date.
The four oncology value frameworks, reviewed in this
study, present notable variations related to the type of decision
being made. Decisions related to the coverage, access and
price of new technologies are some of the most frequently
considered. Some applications have also been concerned with
supporting the construction of appropriate care lines and
facilitating the shared decision-making process.
Table 1 presents a brief description of each of the value
frameworks identified in oncology. Figure 1 presents a general
characterization of these frameworks in terms of decision
context and perspectives adopted. These two aspects can
influence the definition of value adopted, insofar as they
establish how the benefits and costs will be measured (4).
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These new evaluation approaches that are not based on
quality-adjusted life years (QALYs) have been criticized for
having conceptual inconsistency by not including many of
the relevant value criteria for healthcare decisions and for not
adopting well-established procedures to address uncertainty
in the valuation process. For example, some argue that since
oncology-oriented frameworks are methods that have not
been sufficiently tested, input and output choices are con-
fusing, the approach is not patient-oriented, and the overall
process is limited to considering more narrow aspects of
the healthcare system, such as available pharmacological
options. Specifically, in relation to the ASCO framework,
several important components of value are omitted, arbitrary
methods for weighting criteria and eliciting stakeholders’
preferences are adopted, and costs of care are not considered.
Furthermore, it has also been criticized for its lack of well-
established measurement properties (19-22).
Like any healthcare measurement instrument, value assess-
ment frameworks should demonstrate validity (measuring
what it intends to measure) and reliability (consistency in
different applications) (22,23). Different value frameworks
showed convergent validity and good agreement in a compar-
ison of applications made by different evaluators (23). However,
Sorenson et al. observed important limitations in these frame-
works. The ASCO framework did not involve patients in
model design and value assessment, excluding the patient’s
voice from the decision process. The other frameworks offered
only limited access to the economic model underlying the
analyses (13).
Each of the frameworks has considerable limitations,
which must be taken into account when interpreting its
outputs. Whether the different approaches will converge in
the future remains to be seen, but harmonization would help
to limit confusion and aid stakeholders in making informed
decisions in cancer patient care.
Notably, however, treatment ‘‘value’’ is an indefinable
target, and there is no agreement regarding the domains that
truly matter, how they should be incorporated into the tool
(e.g., additive vs multiplicative scoring), or how much weight
should be given to each (4,24).
Multicriteria decision analysis (MCDA)
Thus, some healthcare organizations have proposed guide-
lines that should guide the construction and application of
value frameworks (25,26). These proposals focus on some
principles that should guide future studies, including trans-
parent processes for the development of frameworks, analy-
tical models and reports; patient-centered care and focus on
customizing the decision; access to high-quality scientific
evidence; incorporation of a broad view of the effects; speci-
fication of indications of use and relevant applications; and
inclusion of a wide range of healthcare interventions.
For population-level decisions, CEA and cost-per-QALY
analysis have been recommended as a basis for structuring
the underlying value constructs from the healthcare system
perspective. Elements of value that are not typically captured
in cost or QALY estimates may be considered in future
decision analyses. In this sense, some of the most relevant
elements are productivity, adherence, value of hope, equity
concerns and adjustments for severity of disease to compen-
sate for gains in utility.
Figure 1 - Decision Contexts and Value Frameworks in Oncology.
Source: Schnipper, Davidson, Wollins, Blayney, Dicker, Ganz, et al. (2016), Cherny, Sullivan, Dafni, Kerst, Sobrero, Zielinski, et al. (2015),
The Memorial Sloan Kettering Cancer Center (2016), National Comprehensive Cancer Network (2016).
*Memorial Sloan Kettering Cancer Center; **National Comprehensive Cancer Network; ***American Society of Clinical Oncology;
****European Society of Medical Oncology.
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As the term implies, MCDA involves a set of methods
and processes that allow the multiple criteria involved in a
decision to be explicitly addressed. In this process, clarifica-
tion of the criteria to be considered for the stakeholders
involved and a report of the results of the decisions in a more
transparent way are fundamental. Thus, in the MCDA
methodology, criteria are identified, a score is attributed to
each criterion to reflect its relative importance according to
the different perspectives indicated in the process, evidence
is systematically raised, scores are attributed to the perfor-
mance of the evaluated technologies, and finally, the weighted
scores are aggregated according to the preference of the
participants to constitute a global metric of value (25)
(Figure 2).
Thus, MCDA means considering a broad set of decision
factors that go beyond the clinical benefits of a new health-
care technology to include other elements of value, such as
burden of illness, equity, financial impact, ethical aspects,
level of innovation, and environmental impact.
The first step in conducting MCDA is to identify factors
that are relevant to the decision process. These factors can be
identified from the scientific literature or through consulta-
tions with experts in the area of interest of the technologies
evaluated. The second step involves weighing these factors
based on what different stakeholders understand as relevant
to the decision. Several methodologies may allow interviews
with stakeholders to determine the relative importance of
the criteria. Some of these methodologies are attractive for
simplicity (such as point allocation exercises), and others
are more sophisticated, involving a greater overload on the
participating individuals (such as conjoint approaches). In
the third step, the performance of each of the technologies
can be compared based on the different factors, allowing
the construction of a ranking system (26). Table 2 describes
the eight steps in the implementation of MCDA, based on
a value measurement approach, as recommended by the
International Society For Pharmacoeconomics and Outcomes
Research (ISPOR) Task Force for best practice in MCDA.
One factor that hinders the application of MCDA for
Health Technology Assessment (HTA) methodologies is the
great variability of existing approaches, which makes the
existence of a standard approach difficult to establish. As a
consequence, comparison of MCDA studies is extremely
challenging. Another difficult aspect is the use of MCDA in a
logic of budget constraint optimization, which would imply
translating the value scores derived by MCDA into monetary
values (27).
However, MCDA allows the use of approaches such as
the Paraconsistent Decision Method (PDM), which is able
to synthesize objective information (from previous studies)
and subjective information (from the value judgments of
experts in the area of knowledge), in addition to allowing the
incorporation of conflicting, vague, and incomplete informa-
tion that results from the limitations of the published studies
or the variation in stakeholders perspectives (27).
Some practical aspects for the implementation of this
type of modeling can be highlighted as follows: train
all committee members in the use of MCDA and make
facilitators available to assist in the use of the techniques
in the decision process; select appropriate methods for data
capture (questionnaires, printed or computerized forms, etc.)
and aggregation (specific software); enable the exploration of
the models to ensure the robustness of the criteria, which
can be done in real time or between committee meetings;
and finally, allow the outputs of the models to be visuali-
zed throughout the discussions and incorporated into
the documentation of the report, together with the final
recommendations.
Figure 2 - An Overview of the Multi-Criteria Decision Analysis (MCDA) Process.
Source: Campolina (2017).
Table 2 - Steps in the implementation of Multi-Criteria Decision
Analysis (MCDA), as recommended by the International Society
For Pharmacoeconomics and Outcomes Research (ISPOR) Task
Force for best practice in MCDA.
Step Description
1. Defining the decision
problem
Identify objectives, type of decision,
alternatives, decision makers and output
needed
2. Selecting and
structuring criteria
Identify relevant criteria for assessing
alternative technologies
3. Measuring
performance
Add the performance data of the
alternatives in the established criteria and
summarize in a ‘‘performance matrix’’
4. Scoring alternatives Extracting the preferences of interest
groups for performance variations in the
criteria
5. Weighting criteria Extracting the relative importance of the
established criteria, based on the
preferences of interest groups
6. Calculating aggregate
scores
Use the criteria scores and the weights
assigned to them to obtain the ‘‘total
value’’, through which the alternatives will
be sorted
7. Dealing with
uncertainty
Perform uncertainty analyses to understand
the level of robustness of the results
obtained
8. Reporting and
examination of findings
Interpret analysis results, including
uncertainty analyses, to support decision-
making
Source: Marsh (2016).
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Conclusion
Finally, emerging challenges can be found in relation to the
use of value criteria by oncology frameworks. Even though
the emerging frameworks represent attempts to capture
values that are important to many stakeholders, they are not
always logical or consistent with the principles of decision
theory. In part, these inconsistencies derive from problems
of which perspective has been taken into account (patients,
managers, healthcare professionals, etc.) and how these
different and conflicting perspectives could be aggregated. In
addition, given the lack of use of economic evaluation, value
frameworks in oncology are not consistent with this basic
recommendation for population-level decisions.
Healthcare decision-making that occurs in the absence of
objective evaluation processes may result in discrepancies
in how the importance of values and criteria should be
considered, based on different perspectives. In this sense, the
use of explicit approaches, such as MCDA, can facilitate
the mediation of conflicts and optimize the participation of
different stakeholders.
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